ArticleProstate cancer and prostatic diseases2025

Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison.

Elena Castro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.